Other languages HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Market Closed - London S.E. Other stock markets 11:35:04 2024-05-08 am EDT			5-day change	1st Jan Change
313 ^GBX	+1.62%		+4.33%	+10.60%

10:30am	HUTCHMED Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024	CI
Apr. 26	EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HUTCHMED Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024	04:30am
Hutchmed notes CHMP's positive opinion for fruiquintinib approval	Apr. 26
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer	Apr. 26
Hutchmed to Present New Data at US Cancer Research Conference	Apr. 05
HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024	Apr. 05
Hutchmed endometrial cancer treatment application accepted for review	Apr. 02
HSBC in special payout on Canada sale; Astra FDA win	Apr. 02
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	Apr. 02
Sector Update: Health Care Stocks Advance Premarket Thursday	Mar. 28
Hutchmed lung cancer treatment accepted for review in China	Mar. 28
JD Sports backs outlook; Spirent accepts new offer	Mar. 28
Hutchmed (China)'s NDA Application Accepted by Chinese Authorities	Mar. 28
HUTCHMED Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC	Mar. 27
Hutchmed begins registration stage for sovleplenib phase 2/3 trial	Mar. 22
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug	Mar. 22
Hutchmed (China) Initiates Phase II/III Clinical Trials for Autoimmune Disease Drug	Mar. 22
Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China	Mar. 21
Hutchmed Returns to Profit in 2023; EPS Tops Estimate	Feb. 29
EARNINGS: Hutchmed revenue surges, Craven House's loss widens	Feb. 28
Hutchmed Swings to 2023 Profit as Revenue Increases	Feb. 28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Other languages

Filters